Randomized Comparison of Optimal Medical Therapy and Percutaneous Recanalization for Chronic Total Occlusion (COMET-CTO)

NCT ID: NCT02964975

Last Updated: 2020-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several meta analysis comparing successful Percutaneous Coronary Intervention of Chronic Total Occlusion (PCI-CTO) with unsuccessful PCI-CTO showed that there is significant reduction in short-term and long-term mortality. To our knowledge till today no prospective randomized trial compared percutaneous revascularization of CTO with optimal medical therapy. For this reason quality of live improvement is one of the most important indications for revascularization in elective patients with CTO. In contemporary literature Seattle Angina Questionnaire (SAQ) is a psychometrically solid disease-specific instrument designed to assess the functional status of patients with angina. It comprises 19 questions that quantify five clinically relevant domains: physical limitation, angina stability, angina frequency, treatment satisfaction and disease perception/quality of life.

In this open prospective study patients with CTO of coronary artery will be randomized in two groups: first - patients with percutaneous coronary intervention of chronic total occlusion with optimal medical therapy and second group - patients with only optimal medical therapy (control group). Primary endpoint will be quality of life and secondary endpoints will be mayor adverse cardiovascular events (MACE). All patients will complete Seattle Angina Questionnaire before randomization and after 6 months of follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronary artery chronic total occlusion (CTO) is defined as complete occlusion of coronary arteries that lasts for more than three months (TIMI 0 coronary flow in occluded segment). In absence of serial angiograms , occlusion duration can be assumed based on clinical data regarding event that caused occlusion. Consensus document from the Euro CTO club suggests 3 levels of certainty:

a) Certain (angiographically confirmed): the minority of cases where a previous angiogram (for instance before a previous CABG operation, or after an acute myocardial infarction) has confirmed the presence of TIMI 0 flow for \> 3 months prior to the planned procedure; b) Likely (clinically confirmed): objective evidence of an acute myocardial infarction in the territory of the occluded artery without other possible culprit arteries \>3 months before the current angiogram; c) Possible (undetermined): a CTO with TIMI 0 flow and angiographic anatomy suggestive of long-standing occlusion (collateral development, no contrast staining) with stable angina symptoms unchanged in the last 3 months or evidence of silent ischemia; in case of recent acute ischemic episodes (acute myocardial infarction or unstable angina or worsening effort angina), a culprit artery other than the occluded vessel should be present.

CTO is an often finding. In spite of that, there is uncertainty should this lesions be revascularized and in what way. If there are symptoms or objective proof of ischemia and viability in the area of occluded artery distribution, recanalization of CTO should be considered. Several studies showed that in the presence of chronic total occlusion collateral circulation may produce supply of oxygen and preserve viability. However assessment of collateral circulation with adenosine stress test showed abnormal coronary reserve in over than 90% was reduced which means that collaterals are not enough Therapeutically uncertainties lead partially from technical complex procedures of revascularization CTO with PCI, with success rate of 60-70% which is importantly lower than revascularization rate of non-CTO lesions (98%). During last decade there has been significant improvement in technology, equipment and techniques of percutaneous revascularization procedures for CTO that increased procedural success rate (around 90%). On the other hand there are separate views regarding possibility of treating this patients with coronary artery bypass graft (CABG), and specially patients with single coronary disease Metaanalysis performed by O'Connor SA et al. showed that presence of chronic total occlusion on non infarct artery in patients with acute myocardial infarction significantly increases mortality. Furthermore several mataanalyses that analyzed the effect of PCI CTO on survival, showed significant reduction of mortality rate in short term and also long term follow up. Studies enrolled in this metaanalyses were retrospective or prospective registries which compared successful PCI CTO with PCI CTO failure.

There are different explanations for this clinical result (mortality reduction):

1. direct benefit of achieving coronary flow and myocardial perfusion improves ventricular function and reduces risk of malignant arrhythmias
2. patients in which PCI was unsuccessful probably have more serious coronary atherosclerosis and fibrosis that contribute to procedural failure and greater mortality (3).

Similar to previous metaanalyses study conducted by Prasada et al. showed significantly greater mortality in the group with procedural failure .

Study conducted by Hoye et al. showed significant increase of 5-year mortality rate, CABG and MACE in the group with procedural failure. Authors explained the difference in survival by pharmacological management that can be confounding factor. Also authors stated that better prognosis after successful procedure is probably related to improved left ventricular function and reduced risk of malignant arrhythmias. To our knowledge, there is no prospective randomized study which compared PCI CTO with optimal medical therapy. For this reason quality of life improvement is one of the most important indication for revascularization CTO in elected patients. However, in contemporary literature there is little data regarding quality of life assessment in patients with CTO.

Quality of life assessment is important indicator of successful revascularization in patients with coronary artery disease. "Seattle Angina Questionnaire" (SAQ) is validated for quality of life assessment in patients with coronary artery disease. This questionnaire is based on five different domains : physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. So far quality of life assessment with SAQ was used in four studies. Two of them compared results of SAQ in patients with successful recanalization of CTO and patients with procedural failure. They proved significant improvement in SAQ score in patients with recanalized CTO. Third study compared revascularization strategies (PCI vs. CABG) with optimal medical therapy in patients with diagnosed CTO. In the group treated with medical therapy there were no changes in scores of SAQ domains after one year follow-up, while in patients that were revascularized in CTO territory improvement in SAQ scores were documented in three domains (Physical restraint, angina frequency and disease perception). Fourth study compared quality of life after CTO PCI vs.PCI in on non CTO lesion. In both groups similar improvement was documented in all domains during 6 months follow-up.

So far no prospective randomized study was conducted that examined quality of life in patients with CTO.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Total Occlusions of Coronary Arteries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Optimal medical therapy

conservative treatment

Group Type ACTIVE_COMPARATOR

Optimal medical therapy

Intervention Type DRUG

Medical threatment according to guidelines

Percutaneous coronary intervention

Percutaneous coronary intervention of chronic total occlusion

Group Type ACTIVE_COMPARATOR

Percutaneous coronary intervention

Intervention Type PROCEDURE

Recanalisation of chronic total occlusion of coronary artery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Percutaneous coronary intervention

Recanalisation of chronic total occlusion of coronary artery

Intervention Type PROCEDURE

Optimal medical therapy

Medical threatment according to guidelines

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PCI Angina pectoris opetimal medical therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CTO of coronary artery (TIMI 0 flow)
* a) Stabile angina and/or b) evidence of ischemia in the territory of the CTO and/or c) evidence of viable myocardium in the CTO territory
* target coronary artery with a reference diameter of 2.5 mm

Exclusion Criteria

* acute myocardial infarction in past month
* contraindications for dual antiplatelet therapy in future 12 months
* contraindications for drug eluting stents (DES)
* informed consent not signed
* CTO in bypass graft
* EF \<20 %
* Dementia
* Patient not available for follow-up
* CVI or TIA in past 6 months
* Patients with:

1. neutropenia (\<1000 /mm3) in past two weeks
2. thrombocytopenia (\<100 000/mm3)
3. AST, ALT, alkaline phosphatase \>1.5x the upper limit of normal
4. serum creatine \>2 mg/dL (\>180 µmol/L)
* Patients with allergy to iodine contrast that cannot be treated medically
* Life expectancy not longer than one year
* Patients with bleeding diathesis or coagulopathy or will refuse transfusions.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinical Centre of Serbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sinisa Stojkovic

Head Deaprtment of Interventional Cardiologyand Catheter Ablation, Principal Investigator, Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sinisa Stojkovic, PhD

Role: PRINCIPAL_INVESTIGATOR

Clinical Centre of Serbia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Centre os Serbia

Belgrade, , Serbia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Serbia

References

Explore related publications, articles, or registry entries linked to this study.

Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, Christiansen EH, Gershlick A, Carlino M, Karlas A, Konstantinidis NV, Tomasello SD, Di Mario C, Reifart N; EuroCTO Club. Recanalisation of chronic total coronary occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 2012 May 15;8(1):139-45. doi: 10.4244/EIJV8I1A21. No abstract available.

Reference Type BACKGROUND
PMID: 22580257 (View on PubMed)

Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, Gannot S, Samuel M, Weisbrod M, Bierstone D, Sparkes JD, Wright GA, Strauss BH. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012 Mar 13;59(11):991-7. doi: 10.1016/j.jacc.2011.12.007.

Reference Type BACKGROUND
PMID: 22402070 (View on PubMed)

Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR Jr. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007 Apr 17;49(15):1611-1618. doi: 10.1016/j.jacc.2006.12.040. Epub 2007 Apr 2.

Reference Type BACKGROUND
PMID: 17433951 (View on PubMed)

Werner GS, Bahrmann P, Mutschke O, Emig U, Betge S, Ferrari M, Figulla HR. Determinants of target vessel failure in chronic total coronary occlusions after stent implantation. The influence of collateral function and coronary hemodynamics. J Am Coll Cardiol. 2003 Jul 16;42(2):219-25. doi: 10.1016/s0735-1097(03)00624-7.

Reference Type BACKGROUND
PMID: 12875755 (View on PubMed)

Rathore S, Matsuo H, Terashima M, Kinoshita Y, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura Y, Katoh O, Suzuki T. Procedural and in-hospital outcomes after percutaneous coronary intervention for chronic total occlusions of coronary arteries 2002 to 2008: impact of novel guidewire techniques. JACC Cardiovasc Interv. 2009 Jun;2(6):489-97. doi: 10.1016/j.jcin.2009.04.008.

Reference Type BACKGROUND
PMID: 19539251 (View on PubMed)

Saito S. Progress in angioplasty for chronic total occlusions again. Catheter Cardiovasc Interv. 2010 Nov 15;76(6):850-1. doi: 10.1002/ccd.22847. No abstract available.

Reference Type BACKGROUND
PMID: 21104774 (View on PubMed)

Godino C, Sharp AS, Carlino M, Colombo A. Crossing CTOs-the tips, tricks, and specialist kit that can mean the difference between success and failure. Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1019-46. doi: 10.1002/ccd.22161.

Reference Type BACKGROUND
PMID: 19950136 (View on PubMed)

Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK; COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010 Mar 30;55(13):1348-58. doi: 10.1016/j.jacc.2009.10.062.

Reference Type BACKGROUND
PMID: 20338496 (View on PubMed)

Pancholy SB, Boruah P, Ahmed I, Kwan T, Patel TM, Saito S. Meta-analysis of effect on mortality of percutaneous recanalization of coronary chronic total occlusions using a stent-based strategy. Am J Cardiol. 2013 Feb 15;111(4):521-5. doi: 10.1016/j.amjcard.2012.10.034.

Reference Type BACKGROUND
PMID: 23375252 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OBVSS-30

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Invest-CTO PCI Trial
NCT04774913 ACTIVE_NOT_RECRUITING NA
Chronic Total Occlusion Registry
NCT04041921 TERMINATED
Japanese CTO PCI Expert Registry
NCT01889459 RECRUITING